Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | CD74 | P04233 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL434086 | 0.86 | MIF (0.54) | ALDH1A1KMT2ACD74MIFMEN1 | |
| SCHEMBL18593724 | 0.83 | KCNJ1 (0.45) | GPR55KMT2ADDB1CRBNMIF | |
| SCHEMBL21992183 | 0.80 | MIF (0.52) | ALDH1A1KMT2ACD74MIFMEN1 | |
| SCHEMBL24981984 | 0.79 | GPR55 (0.42) | GPR55ALDH1A1KMT2ADDB1CRBN | |
| SCHEMBL22314900 | 0.78 | MEN1 (0.45) | GPR55ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL20172646 | 0.78 | CTSC (0.41) | ALDH1A1KMT2AHSD11B1PKMSMN1; SMN2 | |
| SCHEMBL782951 | 0.76 | CYP19A1 (0.55) | GPR55 | |
| SCHEMBL10825615 | 0.76 | DDB1 (0.41) | GPR55ALDH1A1DDB1CRBNKCNJ1 | |
| SCHEMBL1025445 | 0.75 | PKM (0.58) | ALDH1A1KMT2AMIFMEN1POLB | |
| SCHEMBL10650193 | 0.75 | CYP11B1 (0.41) | GPR55ALDH1A1SMN1; SMN2RAB9AKCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024148308-A1 | NOVEL, REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED (US) | 2024-07-11 | — | — | WO | disclosed |
| US-11814359-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-11-14 | — | — | US | disclosed |
| US-11773069-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-20230278969-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | BIOPHARMA CREDIT PLC (GB) | 2023-09-07 | — | — | US | disclosed |
| US-20230033573-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | BIOPHARMA CREDIT PLC (GB) | 2023-02-02 | — | — | US | disclosed |
| EP-3323814-B1 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | ASTRAZENECA AB (SE) | 2020-05-13 | — | — | EP | disclosed |
| WO-2020018547-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING LUPUS NEPHRITIS | INSMED INCORPORATED (US) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020018551-A1 | CERTAIN (2S)- N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4- OXAZEPANE-2-CARBOXAMIDES FOR TREATING INFLAMMATORY BOWEL DISEASE | INSMED INCORPORATED (US) | 2020-01-23 | — | — | WO | disclosed |
| EP-3323814-A1 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | AstraZeneca AB (SE) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773069-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | GPR55 3828/4885ALDH1A1 81/4885KMT2A 1794/4885 |
| US-11814359-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | GPR55 3615/4885ALDH1A1 80/4885KMT2A 1598/4885 |
| US-20230278969-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | GPR55 3828/4885ALDH1A1 81/4885KMT2A 1794/4885 |
| US-20230033573-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | GPR55 3828/4885ALDH1A1 81/4885KMT2A 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.